MedPlusMart

Hyderabad, India Founded: 2006 • Age: 20 yrs Listed
General and prescription medicines are ordered via webmobile platform.
Request Access
Report Incorrect Data
Page last updated

About MedPlusMart

MedPlusMart is a publicly listed company based in Hyderabad (India) founded in 2006. General and prescription medicines are ordered via webmobile platform. It operates on a Direct-to-Consumer (D2C) model. MedPlusMart has raised $1.28 million across 2 funding rounds from investors including Srinivas Koppalu, Sridhar Kotagiri and Pratap Ganna. MedPlusMart was last valued at $1.58 million in March 2007. Its website medplusmart.com draws about 1.9 million monthly visits. Its Indian entity Medplus Health Services Limited reported revenue of ₹6,964 Cr. MedPlusMart offers products and services including Medicines. Its focus areas include Online Pharmacy and E-Pharmacy. Its competitors include Tata 1mg, Netmeds and Truemeds; 3 of its 3 listed competitors have raised funding.

Company details

An online pharmacy store is operated in India, focusing on providing medicines through a digital platform. The company serves customers seeking convenient access to healthcare products. Solutions are tailored for direct consumer purchases in the healthcare sector.

Operational Areas
Healthcare → Digital Health & Telemedicine
Key Metrics
  • Market Cap
    ₹7,217 Cr

    MEDPLUS · NSE

  • Share Price
    ₹604.60

    +0.66% today

  • Revenue
    ₹6,892 Cr

    FY 2025-26 · +12.3% YoY

  • EBITDA
    ₹607 Cr

    Margin 8.8%

  • Net Profit
    ₹216 Cr

    FY 2025-26 · +51.2% YoY

  • P/E (TTM)
    34.2x

    P/B 3.5x

  • ROE
    11.8%

    ROCE 12.5%

  • Debt / Equity
    0.68

    Interest cover 37.1x

  • Total Equity Funding
    $1.28M (USD)

    in 2 rounds

  • Latest Funding Round
    $516.76K (USD), Seed

    Mar 2007

Products & Services of MedPlusMart

MedPlusMart offers a comprehensive portfolio of products and services, including Medicines.

Medicines
Pharmacy

Medicines are sold through an online pharmacy platform.

Apps and channels of MedPlusMart

MedPlusMart publishes 2 mobile apps with over 5M+ downloads.

MedPlus Mart - Online Pharmacy
Google Play Medical Everyone Free
Developer: MedPlus Health Services Limited
View on Google Play
MedPlus Mart - Online Pharmacy
App Store Medical 17+
Developer: OPTIVAL HEALTH SOLUTIONS PRIVATE LIMITED
View on App Store

Funding Insights of MedPlusMart

MedPlusMart has successfully raised a total of $1.28M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $516.76 thousand completed in March 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $1.28M
  • Total Rounds 2
  • Last Round Seed — $516,757
  • First Round $766,833

    (Dec 2006)

  • Investors Count 18

All 2 funding rounds of MedPlusMart with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Mar 2007$516,757Seed$1.58M–
–
Dec 2006$766,833Angel Round$4.43MSrinivas Koppalu
Sridhar Kotagiri, Pratap Ganna
Valuation history
DateValuationStage
Mar 2007$1.58M••••••••
Dec 2006$4.43M••••••••

Last known valuation $1.58M (Mar 2007). 18 investors in total: 0 institutional and 18 angel.

Investors in MedPlusMart

MedPlusMart has secured backing from 18 investors, including angel investors. Prominent investors backing the company include Srinivas Koppalu, Sridhar Kotagiri and Pratap Ganna.

All
Angel
InvestorDescriptionFounded YearDomainLocation

Srinivas Koppalu

unknown_72cd8edd5f8943f4b

Sridhar Kotagiri

unknown_b8f9c4fc193340d5b

Pratap Ganna

unknown_636e609b0b844a6d9

Kalyan Bhaskara

unknown_77116448fe8d46338

Ranga Raju

unknown_4384415ca3e84981a

Reema Gupta

unknown_9e727fb569284951b

Mallipudi Mangapati Pallam Raju

unknown_497b9a6e4f0c4bb2a

Sowmya Sri

unknown_f32612d2f4724e518

Santosh Kumar

Angel investor, Co-founder of Flatheads, ex-Unilever executive
unknown_7e185dac401c41ab8

Prasad Vnsv

Angel investor and tech entrepreneur, co-founder of Bobble AI, active in startups
unknown_71384435fe674a7ab
Premium access

Investor details for MedPlusMart

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Medplus Health Services Limited (MedPlusMart)

Medplus Health Services Limited is the primary company behind MedPlusMart. The boards of the 2 registered companies of MedPlusMart currently have 9 directors; the longest-serving is Madhukar Reddy Gangadi, appointed in 2005. 42 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Madhukar Reddy Gangadi
DIN 00098097
Director11 Jul 200521 yrs 3 moOptival Health Solutions Private Limited, Medplus Health Services Limited
Madhavan Ganesan
DIN 01674529
Director05 Aug 20215 yrs 3 moOptival Health Solutions Private Limited
Aparna Surabhi
DIN 01641633
Director22 Nov 20214 yrs 11 moOptival Health Solutions Private Limited, Medplus Health Services Limited
Bhaskar Reddy Cherukupalli
DIN 00926550
Whole-time director14 Feb 20224 yrs 8 moOptival Health Solutions Private Limited, Medplus Health Services Limited
Sujit Kumar Mahato
DIN 07599067
CFO02 Jan 20233 yrs 10 moOptival Health Solutions Private Limited
Manoj Kumar Srivastava
DIN 06518084
Company Secretary27 May 20242 yrs 5 moOptival Health Solutions Private Limited
Muralidharan Thyagarajan
DIN 00052097
Director18 Dec 20241 yr 10 moMedplus Health Services Limited
Mohanakrishna Reddy Arvabumi
DIN 00093185
Director20 May 20265 moMedplus Health Services Limited
Ajit Pandurang Rangnekar
DIN 01676516
Director20 May 20265 moMedplus Health Services Limited

IPO & Listings of MedPlusMart

MedPlusMart is a publicly listed company on the NSE with ticker symbol MEDPLUS in India, operating in the Retail sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • Listed onNSE: MEDPLUS
  • Listed entityMedplus Health Services Limited
  • Exchange sectorRetail

Financials of MedPlusMart

Exchange-reported figures of Medplus Health Services Limited, the listed company behind MedPlusMart (NSE: MEDPLUS).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹6,892 Cr
+12.3% YoY
EBITDA
₹607 Cr
+24.7% YoY
Profit After Tax
₹216 Cr
+51.2% YoY
Net Worth
₹1,975 Cr
+13.5% YoY
Total Assets
₹3,434 Cr
+18.6% YoY
Total Debt
₹1,424 Cr
+27.2% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue6,8926,1365,6254,5583,7793,0692,871
Revenue growth+12.3%+9.1%+23.4%+20.6%+23.1%+6.9%-
EBITDA607487354266272217134
EBITDA margin+8.8%+7.9%+6.3%+5.8%+7.2%+7.1%+4.7%
Profit before tax27518373.4647.1611895.1029.34
Net profit21614362.9347.4093.0962.332.19
Net profit margin+3.1%+2.3%+1.1%+1.0%+2.5%+2.0%+0.1%
EPS (₹)18.3012.565.484.178.031,425.40112.37
Balance sheet
Total assets3,4342,8952,6202,4192,2531,3411,026
Net worth1,9751,7411,5781,4911,418731528
Total debt1,4241,1201,010900815590477
Cash & bank46236714228434.41119141
Net working capital1,5711,3791,1831,1031,291698492
Cash flow
Cash from operations49654014490.411702.89(6.59)
Cash from investing(128)(318)(82.80)429(703)(34.55)(27.55)
Cash from financing(256)(228)(198)(170)440(5.63)89.83
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue2,0371,8801,8641,8061,6791,5431,5101,561
Revenue growth (YoY)+21.3%+21.8%+23.5%+15.7%+6.5%+3.6%--
Other income20.5419.8320.6018.2417.4715.0215.7912.52
EBITDA170133169159149131136133
EBITDA margin+8.3%+7.1%+9.1%+8.8%+8.9%+8.5%+9.0%+8.5%
Depreciation83.8377.9275.9572.7468.5665.6264.2162.47
Interest36.6233.2733.4830.8328.8227.3726.8425.97
Profit before tax70.1541.8880.3573.2968.9452.7661.1156.61
Tax14.088.7116.3715.5013.4310.429.8010.73
Net profit56.0733.1763.9857.7955.5142.3451.3145.88
EPS (₹)4.722.765.334.814.633.534.303.82
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue86171350521414668.3161.11
Revenue growth+20.7%+41.2%+136.1%+46.8%+113.3%+11.8%-
EBITDA10777.8132.196.263.30(8.82)(25.19)
EBITDA margin+12.5%+10.9%+6.4%+2.9%+2.3%-12.9%-41.2%
Profit before tax83.1751.186.957.585.58(8.60)(24.38)
Net profit62.6640.329.335.395.40(8.60)(24.89)
Net profit margin+7.3%+5.7%+1.9%+2.5%+3.7%-12.6%-40.7%
EPS (₹)5.203.370.790.460.47(191.23)(1,282.16)
Balance sheet
Total assets1,4091,3371,2781,2291,158526399
Net worth1,3161,2401,1881,1411,113517396
Total debt91.5594.5188.8485.8044.427.312.56
Cash & bank13957.0263.1590.167.4486.6810.74
Net working capital29921214910862883.748.96
Cash flow
Cash from operations61.9846.688.3711.41(18.37)(6.24)(0.11)
Cash from investing(22.03)(39.19)(24.38)31.72(636)(14.77)(194)
Cash from financing(4.79)(9.91)(5.97)(8.36)56996.94204
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue280223248223206184202177
Revenue growth (YoY)+36.2%+21.1%+22.9%+26.1%+31.6%+3.1%--
Other income4.043.272.492.702.942.652.652.19
Total expenses238194221194179160178158
EBITDA41.8628.9327.4128.7227.0823.9023.8518.69
EBITDA margin+14.9%+13.0%+11.1%+12.9%+13.2%+13.0%+11.8%+10.6%
Depreciation7.866.965.447.197.046.726.516.50
Interest2.802.221.402.402.372.152.082.35
Profit before tax35.2423.0223.0621.8320.6117.6817.9112.03
Tax8.955.576.395.254.984.143.932.66

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 07 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue2,0371,8801,8641,8061,6791,5431,5101,561
Revenue growth (YoY)+21.3%+21.8%+23.5%+15.7%+6.5%+3.6%--
Other income20.5419.8320.6018.2417.4715.0215.7912.52
EBITDA170133169159149131136133
EBITDA margin+8.3%+7.1%+9.1%+8.8%+8.9%+8.5%+9.0%+8.5%
Depreciation83.8377.9275.9572.7468.5665.6264.2162.47
Interest36.6233.2733.4830.8328.8227.3726.8425.97
Profit before tax70.1541.8880.3573.2968.9452.7661.1156.61
Tax14.088.7116.3715.5013.4310.429.8010.73
Net profit56.0733.1763.9857.7955.5142.3451.3145.88
EPS (₹)4.722.765.334.814.633.534.303.82
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue6,8926,1365,6254,5583,7793,0692,871
Revenue growth+12.3%+9.1%+23.4%+20.6%+23.1%+6.9%-
Other income71.3248.6240.0146.0831.3621.5517.28
Total expenses6,2855,6495,2714,2923,5072,8532,737
Employee cost885726626545394339272
EBITDA607487354266272217134
EBITDA margin+8.8%+7.9%+6.3%+5.8%+7.2%+7.1%+4.7%
Depreciation28325022418211988.2774.81
Interest12010396.4383.0366.4354.8546.80
Profit before tax27518373.4647.1611895.1029.34
Tax55.7233.067.86(2.95)23.2231.9927.56
Net profit21614362.9347.4093.0962.332.19
Net profit margin+3.1%+2.3%+1.1%+1.0%+2.5%+2.0%+0.1%
EPS (₹)18.3012.565.484.178.031,425.40112.37
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital24.0123.9423.9123.8623.860.450.19
Reserves & surplus1,9511,7171,5541,4671,394359528
Shareholders' funds (net worth)1,9751,7411,5781,4911,418731528
Minority interest(0.71)(0.66)(0.57)(0.68)(0.52)0.551.30
Secured loans0.000.000.000.00143135105
Unsecured loans1,4241,1201,010900672455372
Total debt1,4241,1201,010900815590477
Total liabilities3,4342,8952,6202,4192,2531,3411,026
Assets
Gross block2,5582,0511,8621,616920618503
Net block1,5951,2961,2421,138799517419
Capital work in progress31.9816.2711.0825.4720.455.544.94
Investments0.000.000.000.030.030.030.25
Inventories1,3821,3451,3401,144915750644
Sundry debtors26.9613.2717.508.656.045.376.40
Cash & bank balances46236714228434.41119141
Loans & advances19811868.1444.1267649.1224.87
Total current assets2,0691,8441,5681,4811,632923816
Total current liabilities498465384378341225323
Net working capital1,5711,3791,1831,1031,291698492
Total assets3,4342,8952,6202,4192,2531,3411,026
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash86.0591.21228(121)(28.42)8.87(46.82)
Net cash from operating activities49654014490.411702.89(6.59)
Net cash from investing activities(128)(318)(82.80)429(703)(34.55)(27.55)
Net cash from financing activities(256)(228)(198)(170)440(5.63)89.83
Net change in cash112(5.16)(137)350(92.81)(37.28)55.68
Closing cash46236714228434.41119141
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+12.3%+9.1%+23.4%+20.6%+23.1%+6.9%-
EBITDA growth+24.7%+37.6%+33.3%-2.5%+25.7%+62.1%-
PBT growth+50.2%+149.5%+55.8%-60.0%+24.0%+224.1%+29.0%
Net income growth+51.2%+127.2%+32.8%-49.1%+49.4%+2746.1%-
Revenue CAGR (3Y)+14.8%+17.5%+22.4%+16.7%+18.5%+12.9%+12.6%
EBITDA CAGR (3Y)+31.7%+21.4%+17.8%+25.7%+31.7%+55.4%+23.8%
Profitability & leverage
Net income margin+3.2%+2.5%+1.2%+1.1%+2.5%+2.1%+0.1%
Return on capital employed+12.5%+10.4%+6.7%+5.6%+10.3%+12.7%+8.7%
Return on net worth+11.8%+9.1%+4.3%+3.5%+8.8%+10.0%+0.4%
Debt / equity0.680.640.620.590.650.851.11
Long-term debt / equity0.600.570.540.480.460.570.79
Interest cover37.1343.2474.2598.7243.4242.7279.51
Efficiency & per share
Fixed asset turnover2.993.143.233.594.925.486.05
Inventory turnover5.064.574.534.434.544.415.53
Debtors turnover342.65398.83430.20620.50662.45521.54378.96
EPS (₹)18.3012.565.484.178.031,425.40112.37
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)164.54145.42132.01124.99118.848,030.0927,206.29
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue280223248223206184202177
Revenue growth (YoY)+36.2%+21.1%+22.9%+26.1%+31.6%+3.1%--
Other income4.043.272.492.702.942.652.652.19
Total expenses238194221194179160178158
EBITDA41.8628.9327.4128.7227.0823.9023.8518.69
EBITDA margin+14.9%+13.0%+11.1%+12.9%+13.2%+13.0%+11.8%+10.6%
Depreciation7.866.965.447.197.046.726.516.50
Interest2.802.221.402.402.372.152.082.35
Profit before tax35.2423.0223.0621.8320.6117.6817.9112.03
Tax8.955.576.395.254.984.143.932.66
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue86171350521414668.3161.11
Revenue growth+20.7%+41.2%+136.1%+46.8%+113.3%+11.8%-
Other income10.778.947.3123.189.542.111.92
Total expenses75363547320814277.1386.30
Employee cost54.3047.2243.6928.1513.7322.586.91
EBITDA10777.8132.196.263.30(8.82)(25.19)
EBITDA margin+12.5%+10.9%+6.4%+2.9%+2.3%-12.9%-41.2%
Depreciation26.3926.9424.1115.314.631.320.84
Interest8.318.638.446.552.630.570.27
Profit before tax83.1751.186.957.585.58(8.60)(24.38)
Tax20.7610.83(2.50)2.040.000.000.51
Net profit62.6640.329.335.395.40(8.60)(24.89)
Net profit margin+7.3%+5.7%+1.9%+2.5%+3.7%-12.6%-40.7%
EPS (₹)5.203.370.790.460.47(191.23)(1,282.16)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital24.0123.9423.9123.8623.860.450.19
Reserves & surplus1,2921,2161,1641,1171,089146395
Shareholders' funds (net worth)1,3161,2401,1881,1411,113517396
Secured loans0.000.000.000.000.000.000.00
Unsecured loans91.5594.5188.8485.8044.427.312.56
Total debt91.5594.5188.8485.8044.427.312.56
Total liabilities1,4091,3371,2781,2291,158526399
Assets
Gross block25825223820188.5825.008.83
Net block16718419217985.0222.687.17
Capital work in progress1.741.230.3517.9115.522.010.95
Investments931928923917418408381
Inventories26.7718.3213.966.693.904.793.94
Sundry debtors13312269.6237.6121.2911.518.60
Cash & bank balances13957.0263.1590.167.4486.6810.74
Loans & advances56.7478.3033.7816.126253.521.63
Total current assets35527518115165710624.91
Total current liabilities56.2262.9331.9143.0229.5522.7615.95
Net working capital29921214910862883.748.96
Total assets1,4091,3371,2781,2291,158526399
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash11.3013.7235.700.9486.6810.740.53
Net cash from operating activities61.9846.688.3711.41(18.37)(6.24)(0.11)
Net cash from investing activities(22.03)(39.19)(24.38)31.72(636)(14.77)(194)
Net cash from financing activities(4.79)(9.91)(5.97)(8.36)56996.94204
Net change in cash35.15(2.42)(21.98)34.77(85.74)75.9410.21
Closing cash13957.0263.1590.167.4486.6810.74
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+20.7%+41.2%+136.1%+46.8%+113.3%+11.8%-
EBITDA growth+37.6%+141.7%+414.2%+89.7%+137.4%+65.0%-
PBT growth+62.5%+636.4%-8.3%+35.8%+9998.0%+64.7%-848.6%
Net income growth+55.4%+332.2%+73.1%-0.2%+162.8%+65.5%-
Revenue CAGR (3Y)+59.0%+69.8%+94.8%+51.8%+148.3%+93.6%+204.7%
EBITDA CAGR (3Y)+157.7%+186.8%---+21.9%+135.5%
Profitability & leverage
Net income margin+7.3%+5.7%+1.9%+2.6%+3.8%-12.6%-40.7%
Return on capital employed+6.5%+4.3%+1.1%+1.1%+0.9%0.0%0.0%
Return on net worth+4.8%+3.1%+0.7%+0.4%+0.6%0.0%0.0%
Debt / equity0.070.080.070.060.030.010.00
Long-term debt / equity0.070.070.070.050.030.010.00
Interest cover10.3016.96104.46-72.38-197.74-5.62-1.04
Efficiency & per share
Fixed asset turnover3.372.912.301.482.574.0412.03
Inventory turnover38.1744.1848.9340.4033.5415.6529.31
Debtors turnover6.777.469.427.268.886.7911.44
EPS (₹)5.203.370.790.460.47(191.23)(1,282.16)
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)109.63103.6399.3695.6693.283,273.9720,392.16

Timeline of MedPlusMart

4 dated milestones of MedPlusMart across 1 years, from founding to its latest funding, stage changes and deals.

  1. Founded MedPlusMart is founded.
  2. Funding First funding round of $767K.
  3. Milestone Reaches Minicorn status.
  4. Funding Latest funding round, Seed, of $517K.

Competitors of MedPlusMart

MedPlusMart has 3 listed competitors in our database, 3 of them funded. They include Tata 1mg, Netmeds and Truemeds.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Tata 1mg
1mg.com2015Delhi, India$230.8M4,419
Provider of an online pharmacy with doctor listing and teleconsultation services
Netmeds
netmeds.com2015Chennai, India$109M988
Provider of an online store for medicines and healthcare products
Truemeds
truemeds.in2019Mumbai, India$112.97M345
Provider of an online pharmacy and telehealth platform
Premium access

Detailed competitors of MedPlusMart

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of MedPlusMart

The website of MedPlusMart (medplusmart.com) receives about 1.9M visits a month and ranks #27,494 among all websites worldwide, #636 in Pharmacy.

  • Monthly visits
    1.9M

    ▲ 5.1% vs previous month

  • Unique visitors
    953.7K

    per month

  • Global rank
    #27,494

    among all websites

  • Category rank
    #636

    Health · Pharmacy

Similar websites

Websites whose visitors overlap most with MedPlusMart. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
apollopharmacy.in
apollopharmacy.in
100%
#3,790–
PharmEasy
pharmeasy.in
96%
9.4M#6,526View details
Netmeds
netmeds.com
96%
6.3M#10,624View details
MedPlus
medplusindia.com
87%
38.3K#564,350View details
Tata 1mg
1mg.com
72%
44.9M#1,062View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 40 similar websites and full traffic analytics for MedPlusMart

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 40 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Digital Health & Telemedicine

3 companies that operate in the same segment as MedPlusMart (Digital Health & Telemedicine) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Tata 1mg
Provider of an online pharmacy with doctor listing and teleconsultation services
2015Delhi, Delhi, IndiaUSD 199.65 MUSD 328.97 M5,212
MediBuddy
Online platform offering multiple healthcare services
2013Bengaluru, Karnataka, IndiaUSD 199.22 MUSD 62.4 M52
SastaSundar
An online marketplace for healthcare products is operated.
2011Kolkata, West Bengal, IndiaUSD 38.26 M
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Medplusmart

Startoon Labs and Medplus Partner to Introduce Pheezee Joint Health Assessment
Mediabulletins • 1 year ago
Startoon Labs signs MoU with pharmacy retail chain Medplus
Biospectrumindia • 1 year ago
Startoon Labs Partners with Medplus for Joint Health Assessments using Pheezee Device
Onlinemediacafe • 1 year ago
Medplus stock slips 3% after 12.8% equity changes hands in Rs 950 crore large trade
Moneycontrol • 2 years ago
Why retail pharmacies have a bone to pick with their online counterparts
Yourstory • 2 years ago
Medplus decides against fund raising, puts diagnostic expansion on hold
B2Bchief • 2 years ago
India's MedPlus Health Q2 profit more than doubles on strong demand
Zawya • 3 years ago
Home care shop Mediplus merges with industry peer Medicura
Skipr • 3 years ago
MedPlus Health's PAT dipped 25.70% yoy at Rs20.02crore
Indiainfoline • 4 years ago
Medicover Romania consolidates its services dedicated to women’s health, by acquiring Mediplus Clinic
Business-Review • 4 years ago
Premium access

Complete news archive for MedPlusMart

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about MedPlusMart

MedPlusMart was founded in 2006.

MedPlusMart is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.

MedPlusMart is a funded company, having raised a total of $1.28M across 2 funding rounds to date. The company's 1st funding round was a Angel Round of $766.83K, raised on Dec 2006.

The primary company behind MedPlusMart, Medplus Health Services Limited, reported revenue of ₹6,964 Cr for FY 2026, up 12% year on year.

An online pharmacy store is operated in India, focusing on providing medicines through a digital platform. The company serves customers seeking convenient access to healthcare products. Solutions are tailored for direct consumer purchases in the healthcare sector.

MedPlusMart's top competitors include Tata 1mg, Truemeds and Netmeds.

MedPlusMart offers Medicines.

Yes, MedPlusMart is publicly traded on NSE under the ticker symbol MEDPLUS.

MedPlusMart has 18 investors. Key investors include Srinivas Koppalu, Sridhar Kotagiri, Pratap Ganna, Kalyan Bhaskara, and Ranga Raju.

The valuation of MedPlusMart is $1.58M as of Mar 2007.

MedPlusMart is associated with 2 legal entities: Medplus Health Services Limited, Optival Health Solutions Private Limited.

The legal entities of MedPlusMart currently have 10 directors, including Madhukar Reddy Gangadi, Manoj Kumar Srivastava, Sujit Kumar Mahato and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available